BiotechTube
TriArm Therapeutics

TriArm Therapeutics

New York, United States· Est.
triarm.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

TriArm Therapeutics is a private, clinical-stage biotechnology company founded in 2019 and headquartered in New York, USA. The company is developing a pipeline of CAR-T cell therapies using its core non-viral platform, which aims to improve safety profiles, reduce manufacturing complexity, and lower costs compared to current approved CAR-T products. This strategy targets a significant unmet need by making these potentially curative treatments accessible to a broader global patient population, including those in emerging markets. As a pre-revenue company, TriArm is executing on its clinical programs to validate its platform and attract potential partnerships or further investment.

Oncology

Technology Platform

Proprietary non-viral platform for engineering CAR-T cells, aiming to reduce manufacturing complexity, cost, and improve safety profiles compared to viral vector-based methods.

Funding History

1
Total raised:$30M
Series A$30M

Opportunities

The high cost and manufacturing complexity of current CAR-T therapies create a vast opportunity for a platform that can reduce both.
Expanding access to global markets, particularly cost-sensitive regions, represents a significant growth avenue.
Success in solid tumors would unlock a market orders of magnitude larger than current hematological indications.

Risk Factors

High risk of clinical failure inherent to novel drug development.
Faces intense competition from both approved products and numerous next-generation CAR-T developers.
Regulatory pathway for non-viral gene editing technologies may be uncertain and require extensive safety data.
Reliant on external financing as a pre-revenue company.

Competitive Landscape

TriArm competes in the crowded next-generation CAR-T space, facing off against other companies developing non-viral, off-the-shelf, or improved safety profile CAR-Ts. Key competitors include large pharma (e.g., Novartis, Gilead, Bristol Myers Squibb) with approved products and vast resources, as well as agile biotechs like Caribou Biosciences, Precision BioSciences, and Allogene Therapeutics. Differentiation will depend on clinical data demonstrating superior cost, safety, or efficacy.

More companies in Cell & Gene Therapy →More companies in United States →